IHC analyses further showed stronger nuclear YAP1 and FAPα immunoreactivity in stromal fibroblasts of tumors obtained from the NPC patients diagnosed with distant metastasis compared with that in the patients with complete tumor remission after therapy (p = 0.0185 and 0.0162 for YAP1 and FAPα, respectively) (Fig. 1E and F). This evidence concerns the gene YAP1 and neoplasm.